ProQR Therapeutics (PRQR) Stock Forecast & Price Target

ProQR Therapeutics is supported by an increasingly differentiated NTCP-editing platform that has already shown proof of concept in humans, with AX-0810 producing dose-dependent increases in circulating TUDCA, conjugated bile acids, and serum total bile acids, plus a favorable safety profile with no SAEs or pruritus to date. The next-generation AX-0811 program appears more potent, with preclinical data showing a 67% decrease in hepatocyte bile acid levels, a 67% improvement in cholestasis score, and projected 40% editing at 2 mg/kg and 65% at 4 mg/kg in human liver, which could strengthen translational confidence. Financially, the company bolstered its balance sheet with a $50 million offering and a $9.2 million private placement, extending its operational runway into 2H28 and funding the planned clinical path in biliary atresia.

ProQR Therapeutics is weighed down by persistent cash burn and a likely need for additional debt or equity financing, which could be dilutive or come with restrictive covenants and may be hard to secure on acceptable terms. Its RNA pipeline also faces substantial execution risk, as the BA program requires a narrow patient-enrichment window, uncertain biomarker selection, and a difficult regulatory path for proving durable non-progression endpoints. In addition, weak patent protection, potential IP litigation costs, safety and clinical trial setbacks, and intense competition from better-funded biotech and pharma rivals all threaten commercialization and long-term value creation.